


The Fund's investment objective is to achieve long-term capital growth.
| Name | % Net Assets |
|---|---|
| Booker Group | 4.2% |
| Patsystems | 3.9% |
| Immunodiagnostic Systems Hldgs | 3.6% |
| Filtrona | 3.5% |
| Omega insurance Holdings Ltd. | 3.3% |
| John Menzies | 3.0% |
| Pace | 2.9% |
| Dignity | 2.8% |
| Elements | 2.8% |
| Xaar | 2.5% |
| Key | % Net Assets |
|---|---|
| 4.2% | |
| 3.9% | |
| 3.6% | |
| 3.5% | |
| 84.8% |
| Date | 31-May-2023 |
|---|---|
| NAV | 427.20p |
| Currency | GBP |
| Change | -2.70p |
| % | -0.63% |
| YTD change | 427.20p |
| YTD % | n/a |
| Fund Inception | 02/08/1996 |
|---|---|
| Fund Manager | Paul Marriage |
| TER | 1.26 (30-Apr-2011) |
| Minimum Investment | |
|---|---|
| Initial | £25000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.00% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.26 |
You are here: research